The genetic testing platform detecting and measuring disease.
This company is not in the game right now, so it has no score sheet.
Points come from real numbers anyone can check: new job posts, site traffic, software downloads and confirmed news. How scoring works
Facts from Y Combinator’s public list, last updated Nov 15. A free game. No real money. Points are a game score, not a judgment of what a company is worth.
Something wrong, or want this page gone? Fix or remove this page. Removal requests from a company's team are always honored. Founder of BillionToOne? Claim this page for a Founder-verified badge and your own pitch.
BillionToOne sells genetic tests that count DNA fragments to detect and measure disease, mainly for pregnancy screening and cancer monitoring.
Think of it as Quest Diagnostics, but counting DNA fragments one by one.
Doctors often need a blood test that finds disease early or tracks it over time. Older tests can miss small signals or give fuzzy numbers, so patients get repeat tests, false alarms, or unclear results.
A patient gives a blood sample. The lab reads the cell-free DNA floating in it and tags each fragment with a unique barcode, so it can count the exact number of fragments from each source. That count gives a precise measurement, not just a yes or no.
Doctors and hospitals order the tests, and insurers or patients pay. Pricing is usually per test, with insurers reimbursing a set fee for each covered test.
This is the blood-based genetic testing category, which is large and crowded, with a few big labs and several well-funded startups. BillionToOne sits in the group focused on precise DNA measurement for pregnancy and cancer care.
Why now: Cheaper DNA sequencing and better lab barcoding now let labs count tiny amounts of DNA in a regular blood draw, which makes routine testing practical.
Written by AI from the company's public site. Not checked by the company. Something wrong? Fix it.